diallyl trisulfide has been researched along with Carcinoma, Anaplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, J; Cheng, X; Lu, R; Pan, J; Xu, S; Yu, H; Zhang, L; Zheng, J | 1 |
| Cha, HJ; Choi, YH; Kim, GY; Kim, WJ; Shin, DY | 1 |
2 other study(ies) available for diallyl trisulfide and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Diallyl trisulfide induces G2/M cell-cycle arrest and apoptosis in anaplastic thyroid carcinoma 8505C cells.
Topics: Allyl Compounds; Antioxidants; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Survival; DNA Damage; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Histones; Humans; Reactive Oxygen Species; Sulfides; Thyroid Neoplasms | 2019 |
Inhibiting invasion into human bladder carcinoma 5637 cells with diallyl trisulfide by inhibiting matrix metalloproteinase activities and tightening tight junctions.
Topics: Allyl Compounds; Carcinoma; Cell Line, Tumor; Cell Movement; Claudins; Down-Regulation; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Sulfides; Tight Junctions; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Urinary Bladder Neoplasms | 2013 |